Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TSVT - 2seventy bio Inc


IEX Last Trade
4.865
0.045   0.925%

Share volume: 223,238
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$4.82
0.05
0.93%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
9%
Profitability 0%
Dept financing 14%
Liquidity 69%
Performance 3%
Company vs Stock growth
vs
Performance
5 Days
2.53%
1 Month
-1.02%
3 Months
11.70%
6 Months
-10.48%
1 Year
-9.31%
2 Year
-66.30%
Key data
Stock price
$4.86
P/E Ratio 
-1.61
DAY RANGE
N/A - N/A
EPS 
-$2.98
52 WEEK RANGE
$1.54 - $6.40
52 WEEK CHANGE
-$0.06
MARKET CAP 
250.795 M
YIELD 
N/A
SHARES OUTSTANDING 
51.498 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.42
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$242,365
AVERAGE 30 VOLUME 
$325,740
Company detail
CEO: Nick Leschly
Region: US
Website: 2seventybio.com
Employees: 114
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

we are an immuno-oncology cell therapy company focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. our name, 2seventy bio, is inspired by the maximum speed of translating human thought into action—270 miles per hour, and at 2seventy, we think in the language of time. with a deep understanding of cancer cell metabolism, genomics, and the human body’s immune response to tumor cells, we’re applying this knowledge and expertise to new classes of cellular therapies that are designed to “think” smarter and faster than cancer. it is this mindset that propels us forward because we know that time matters -- every day, every minute, every second -- to people living with cancer

Recent news